Episode 67 of Boardroom Conversations with Fexingo takes you inside the boardroom of Novo Nordisk, the Danish pharmaceutical giant that turned a diabetes drug into a weight-loss phenomenon. Lucas and Luna explore how the board navigated the explosive demand for Ozempic and Wegovy, managing supply constraints, pricing controversies, and a 400% stock surge over three years. They break down the board's decision to invest $6 billion in new manufacturing capacity, the ethical tightrope of marketing obesity drugs, and how they fended off competition from Eli Lilly. Specific numbers, dates, and strategic pivots give listeners a concrete understanding of corporate governance at a company that tripled its market cap in 18 months. A must-hear for anyone interested in pharma strategy, boardroom risk-taking, and the business of global health trends.